Hu Hai

1 clinical trials · Sponsor

Record	Firm	Date
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation (NCT07441512)	Hu Hai	2026-03-15

Every clearance here is in the API, with alerts when new ones post.